Dalton Pharma Services Boosts Aseptic Powder Fill-Finish Operations with RoboFil™ in Toronto

Dalton Pharma Services Announces Major Expansion in Toronto

Dalton Pharma Services, a well-established leader in pharmaceutical production, has recently made a significant upgrade to its facility in Toronto, Canada. The company has successfully installed the state-of-the-art RoboFil™ aseptic powder fill-finish system, marking a pivotal advancement in its operational capabilities.

This fully automated platform not only increases the aseptic powder fill-finish capacity but also reinforces Dalton's stronghold in the pharmaceutical market. The RoboFil™ system is specially designed to ensure high standards of sterility, precise dosing, and consistent process control, which are crucial in the manufacturing of clinical supplies and commercial products.

Innovative Technology for Enhanced Efficiency

The RoboFil™ line utilizes robotic handling combined with isolator technology, addressing one of the primary risks in aseptic operations—operator intervention. With this innovative approach, Dalton Pharma can significantly minimize the chances of contamination, which is a critical concern in the pharmaceutical industry. The system also offers remarkable flexibility, facilitating rapid changeovers between different vial formats. This capability is essential for supporting a broad range of production needs, from initial development batches to large-scale Good Manufacturing Practice (GMP) operations.

Dr. Jixing Wang, the President of Dalton Pharma Services, commented on the installation, stating, "RoboFil™ reflects Dalton's commitment to investing in advanced technologies that enable our clients to execute aseptic powder fill-finish with confidence. This Annex 1–aligned robotic isolator platform expands both our capacity and operational flexibility, supporting programs from early clinical supply through scalable commercial manufacturing."

A Testament to Dalton's Excellence

Dalton Pharma Services boasts 37 years of expertise in the field, with a well-integrated single-site model that encompasses Active Pharmaceutical Ingredient (API) development, cGMP manufacturing, formulation, aseptic fill-finish processes, and rigorous in-house quality control and microbiological testing. The company continues to partner with biotech and pharmaceutical firms globally, providing essential support in the development and manufacturing of life-enhancing therapies.

Moreover, the company is proud of its diverse team, which includes professionals from over 40 nationalities, including 44 hold advanced degrees (MS/PhD). With a proven track record of over 3,000 production campaigns, Dalton Pharma Services remains dedicated to driving innovation and ensuring quality in every step of the manufacturing process.

In conclusion, the launch of the RoboFil™ system signifies a transformative leap forward for Dalton Pharma Services, underscoring its pledge to innovation and quality. As the company continues to fortify its capabilities in aseptic powder fill-finish processes, it remains devoted to facilitating the success of its partners in the pharmaceutical industry.

For further details, visit Dalton Pharma Services Website.